Redhill Biopharma Ltd
RDHL
$11.01
Closing
▲2.51%
1D
▼-69.84%
YTD
RDHL
BBG003RY92J5
Market cap
$14.10M
52 week high
$82.00
52 week low
$6.67
Volume
6,812
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$14.10M
Analysts' Rating
BUY
Price Target (Mean)
19000.00
Total Analysts
0
P/E
Operating Margin
0.00%
Beta
3.66
Revenue Growth
0.00%
52 week high
$82.00
52 week low
$6.67
Div. Yield
%
EPS Growth
0.00
Company Profile
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn’s disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
